Lazolvan - instructions for use, analogs, testimonials and release forms (30 mg tablets, syrup, inhalation solution, pastilles 15 mg) for cough and bronchitis in adults, children and pregnancy

In this article, you can read the instructions for using the drug Lazolvan. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Lazolvana in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Lazolvana in the presence of existing structural analogues. Use for the treatment of bronchitis, pneumonia and cough in adults, children, as well as during pregnancy and lactation.

Lazolvan mucolytic drug.

In studies, it was shown that Ambroxol (the active substance of the drug Lazolvan) increases secretion in the respiratory tract. Strengthens the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased current and transport of mucus (mucociliary clearance). Strengthening mucociliary clearance improves sputum discharge and facilitates coughing.

Pharmacokinetics

Lazolvan is characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic concentration range. The transfer of ambroxol from the blood to the tissue with oral administration occurs rapidly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of the dose taken is exposed to the effect of "first passage" through the liver. The rest of the ambroxol is metabolized in the liver, mainly by conjugation.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

• acute and chronic bronchitis;
• pneumonia;
• chronic obstructive pulmonary disease;
• bronchial asthma with difficulty in sputum discharge;
• bronchiectatic disease.

Forms of release

Tablets 30 mg.

Syrup (child form of the drug).

Solution for ingestion and inhalation.

Lozenges 15 mg.

Instructions for use and dosage

The drug in the form of tablets is prescribed to adults 30 mg 3 times a day.

If necessary, to increase the therapeutic effect, you can appoint 60 mg twice a day. Tablets are taken after meals, washed down with liquid.

The drug in the form of a syrup of 15 mg / 5 ml is prescribed for adults and children over 12 years of 10 ml (2 teaspoons) 3 times a day; children aged 6 to 12 years - 5 ml (1 teaspoon) 2-3 times a day; Children aged 2 to 6 years are prescribed 2.5 ml (1/2 teaspoon) 3 times a day; children under 2 years - 2.5 ml (1/2 teaspoon) 2 times a day.

The drug in the form of a syrup of 30 mg / 5 ml for adults and children over 12 years of age appoint 5 ml (1 teaspoon) 3 times a day; children aged 6 to 12 years - 2.5 ml (1/2 teaspoon) 2-3 times a day.

Taking the drug for more than 4-5 days is possible only under the supervision of a doctor.

Lazolvan in the form of a syrup should be taken with food, squeezed with liquid.

Lazolvan in the form of a solution for inhalation can be used with any modern inhalation device, in addition to inhalers of evaporation type.The drug is mixed with a physiological solution in a 1: 1 ratio to achieve optimal air humidification in the respirator.

During inhalation, in order to avoid a cough reflex caused by a deep breath, the patient should breathe calmly. It is recommended to warm the inhalable solution to body temperature. Patients with bronchial asthma are advised to do inhalations after taking bronchodilators.

Side effect

• heartburn;
• dyspepsia;
• nausea, vomiting;
• diarrhea;
• skin rash;
• hives;
• angioedema;
• anaphylactic reactions (including anaphylactic shock).

Contraindications

• 1 trimester of pregnancy;
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Lazolvan penetrates the placental barrier.

In experimental studies on animals, there was no direct or indirect adverse effect on pregnancy, embryonic, prenatal and postnatal development and on childbirth.

Clinical studies during the 28 weeks of pregnancy found no evidence of a negative effect of the drug on the fetus.

Nevertheless, it is necessary to observe the usual precautions when using the drug during pregnancy. Especially it is not recommended to take Lazolvan in the 1st trimester of pregnancy.

Ambroxol can excrete with human milk. Therefore, it is not recommended to prescribe Lazolvan to nursing mothers. However, the adverse effect in newborns is unlikely.

special instructions

Do not use in combination with antitussive drugs that make it difficult to remove phlegm.

Lazolvan Syrup (15 mg / 5 ml) contains 10.5 g of sorbitol in terms of the maximum recommended daily dose (30 ml). Patients with a rare hereditary intolerance to fructose should not take this drug. It can also have a mild laxative effect.

Lazolvan Syrup (30 mg / 5 ml) contains 5 g of sorbitol in terms of the maximum recommended daily dose (20 ml). Patients with a rare hereditary intolerance to fructose should not take this drug.

Lazolvan tablets (30 mg) contain 684 mg of lactose in terms of the maximum recommended daily dose (120 mg). Patients with rare hereditary intolerance to galactose, deficient lactase Lapp, or impaired glucose / galactose absorption, should not take this drug.

Registered very rare cases of severe skin lesions, for example, Stevens-Johnson syndrome and Lyell's syndrome; however, the connection with the drug is not proven. With the development of the above syndromes, it is recommended to stop treatment and immediately seek medical help.

Drug Interactions

Simultaneous use with antitussive drugs leads to difficulty in withdrawing sputum on the background of a reduction in cough.

Ambroxol increases the penetration into the bronchial secret of amoxicillin, cefuroxime, erythromycin, doxycycline.

Lazolvan is compatible with drugs that inhibit labor.

Analogues of Lazolvan drug

Structural analogs for the active substance:

• Ambrogen;
• AmbroGEXAL;
• Ambroxol;
• Ambroxol Vramed;
• Ambroxol retard;
• Ambroxol-Verte;
• Ambroxol-Vial;
• Ambroxol-Richter;
• Ambroxol-Teva;
• Ambroxol-Hemofarm;
• Ambrolan;
• Ambrosan;
• Ambrosol;
• Bronoxoxol;
• Bronchorus;
• Dephlegmine;
• Bronchovern drops;
• Lazolangin;
• Medox;
• Mucobron;
• Neo-Bronhol;
• Remebroks;
• Suprima-kof;
• Fervex from coughing;
• Flavamed;
• Haliksol.

Similar medicines:

Other medicines: